HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) All Versions of this Article: 0091270008315316v1 48/5/580    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (4) Citing Articles via Google Scholar Google Scholar Articles by Roethig, H. J. Articles by Zedler, B. K. Search for Related Content PubMed PubMed Citation Articles by Roethig, H. J. Articles by Zedler, B. K. Social Bookmarking                         What's this?

A 12-Month, Randomized, Controlled Study to Evaluate Exposure and Cardiovascular Risk Factors in Adult Smokers Switching From Conventional Cigarettes to a Second-Generation Electrically Heated Cigarette Smoking System

From Philip Morris USA, Richmond, Virginia.

This randomized, controlled, forced-switching, open-label, parallel-group study in 97 adult male and female smokers of conventional cigarettes evaluated biomarkers of tobacco smoke exposure and cardiovascular risk factors. After baseline measurements, smokers were either switched to a second-generation electrically heated cigarette smoking system (EHCSS) or continued smoking conventional cigarettes for 12 months. Biomarkers of exposure and cardiovascular risk factors were measured at 0.5, 1, 2, 3, 4, 5, 6, 9, and 12 months. There was a rapid and sustained reduction in all biomarkers of exposure after switching to the EHCSS, with statistically significant reductions from baseline in nicotine equivalents (-18%), plasma cotinine (-16%), total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (-73%), total 1-hydroxypyrene (-53%), urine mutagenicity (-52%), 4-aminobiphenyl hemoglobin adducts (-43%), carboxyhemoglobin AUC_{7-23 h} (-80%), and 3-hydroxypropylmercapturic acid (-35%). These reductions in exposure in the EHCSS group were associated with statistically significant and pathophysiologically favorable changes in several cardiovascular risk factors, including white blood cell count (-0.78 x 10³/µL), hemoglobin (-0.16 g/dL), hematocrit (-0.44%), urine 11-dehydrothromboxane B₂ (-374 ng/24 h), and high-density lipoprotein cholesterol (+5 mg/dL).

Key Words: Biomarkers • exposure • cardiovascular risk factors • EHCSS • potential reduced-exposure tobacco product

Address for correspondence: Hans J. Roethig, MD, PhD, FCP, FFPM, Philip Morris USA Inc, Research Center, 4201 Commerce Road, Richmond, VA 23234; e-mail: hans-juergen.roethig{at}pmusa.com.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D. K. Hatsukami, K. Hanson, A. Briggs, M. Parascandola, J. M. Genkinger, R. O'Connor, and P. G. Shields Clinical Trials Methods for Evaluation of Potential Reduced Exposure Products Cancer Epidemiol. Biomarkers Prev., December 1, 2009; 18(12): 3143 - 3195. [Abstract] [Full Text] [PDF]

				R. J. O'Connor, K. M. Cummings, V. W. Rees, G. N. Connolly, K. J. Norton, D. Sweanor, M. Parascandola, D. K. Hatsukami, and P. G. Shields Surveillance Methods for Identifying, Characterizing, and Monitoring Tobacco Products: Potential Reduced Exposure Products as an Example Cancer Epidemiol. Biomarkers Prev., December 1, 2009; 18(12): 3334 - 3348. [Abstract] [Full Text] [PDF]

				M. Zeller, D. Hatsukami, and and the Strategic Dialogue on Tobacco Harm Reducti The Strategic Dialogue on Tobacco Harm Reduction: a vision and blueprint for action in the US Tob. Control, August 1, 2009; 18(4): 324 - 332. [Abstract] [Full Text] [PDF]